Pharmaceutical industry in the US to grow to $615 B by 2022

reogma|Pharmaceutical industry in the US to grow to $615 B by 2022

The US pharmaceutical market is estimated to grow by 4-7% CAGR from USD 489.93 billion in 2018 to USD 585-615 billion in 2022.

  • Definition / Scope
  • Market Overview
  • Market Risks
  • Top Market Opportunities
  • Market Trends
  • Industry Challenges
  • Technology Trends
  • Pricing Trends
  • Regulatory Trends
  • Other Key Market Trends
  • Market Size and Forecast
  • Market Outlook
  • Technology Roadmap
  • Distribution Chain Analysis
  • Competitive Landscape
  • Competitive Factors
  • Key Market Players
  • Strategic Conclusion
  • References
  • Appendix

Definition / Scope

Drug manufacturing is one of the major industry that deploys scientific and technological advances the most for its jobs to be done. The industry develops novel drugs that result in substantial socioeconomic benefits from improved patient outcomes, reduced mortality, and increased efficiency. In addition, the industry is a generator of high-value, high-wage jobs that fuel local and regional economies around the country.

Drugs (biopharmaceuticals, drugs, medicines) are defined as any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or any substance (other than food) intended to affect the structure or function of the body. Drugs are produced in forms such as pills, tablets, capsules, etc.

Generic drugs are copies of innovative pharmaceuticals that contain the same active ingredients and are identical in strength, dosage form and route of administration and are comparatively cheaper than the innovative ones. Generic drugs are further divided into two types:

  • Commodity generics are those marketed as a chemical name
  • Branded generics are those marketed by a drug company under its own label and typically command higher prices than non-brand generics

Biologics (biotech drugs, biological drugs, biopharmaceuticals) include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc.

Biosimilars (follow-on biologics) are versions of biologic products that reference the originator product in applications submitted for marketing approval to a regulatory body.


This report is 16 mins read | Subscribe now to read further.

Access all reports on site for only US$9.99/mo


Leave a Reply

Next Post

Mobile field service management market in the US to grow at 22% by 2025

Wed Dec 18 , 2019
The US pharmaceutical market is estimated to grow by 4-7% CAGR from USD 489.93 billion in 2018 to USD 585-615 billion in 2022. Definition / Scope Market Overview Market Risks Top Market Opportunities Market Trends Industry Challenges Technology Trends Pricing Trends Regulatory Trends Other Key Market Trends Market Size and […]
reogma|Pharmaceutical industry in the US to grow to $615 B by 2022reogma|Pharmaceutical industry in the US to grow to $615 B by 2022

Tags

Tags

Newsletter Signup

Subscribe to our newsletter below and never miss the latest product or an exclusive offer.